# Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

> **NCT01089088** · PHASE2 · COMPLETED · sponsor: **Cardiff University** · enrollment: 63 (actual)

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter
- Urethral Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT01089088
- **Lead sponsor:** Cardiff University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2018-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01089088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01089088, "Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01089088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*